ES2556585T3 - Composiciones que comprenden sulfato de salbutamol - Google Patents
Composiciones que comprenden sulfato de salbutamol Download PDFInfo
- Publication number
- ES2556585T3 ES2556585T3 ES12787053.3T ES12787053T ES2556585T3 ES 2556585 T3 ES2556585 T3 ES 2556585T3 ES 12787053 T ES12787053 T ES 12787053T ES 2556585 T3 ES2556585 T3 ES 2556585T3
- Authority
- ES
- Spain
- Prior art keywords
- compositions
- salbutamol sulfate
- consisting essentially
- component consisting
- salbutamol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201117621A GB201117621D0 (en) | 2011-10-12 | 2011-10-12 | Compositions |
| GB201117621 | 2011-10-12 | ||
| PCT/GB2012/052542 WO2013054135A1 (en) | 2011-10-12 | 2012-10-12 | Compositions comprising salbutamol sulphate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2556585T3 true ES2556585T3 (es) | 2016-01-19 |
Family
ID=45091933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12787053.3T Active ES2556585T3 (es) | 2011-10-12 | 2012-10-12 | Composiciones que comprenden sulfato de salbutamol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9114164B2 (enExample) |
| EP (1) | EP2766005B1 (enExample) |
| JP (1) | JP5818290B2 (enExample) |
| CN (1) | CN103857388B (enExample) |
| AU (1) | AU2012322453B2 (enExample) |
| BR (1) | BR112014008609B1 (enExample) |
| CA (1) | CA2851764C (enExample) |
| ES (1) | ES2556585T3 (enExample) |
| GB (1) | GB201117621D0 (enExample) |
| MX (1) | MX336225B (enExample) |
| WO (1) | WO2013054135A1 (enExample) |
| ZA (1) | ZA201402234B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
| CN107206000A (zh) | 2014-12-22 | 2017-09-26 | 阿鲁兹特拉生物有限公司 | 预防和治疗血小板增多的癌症患者中的转移性疾病 |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| ES2796177T5 (es) * | 2015-12-04 | 2024-10-29 | Mexichem Fluor Sa De Cv | Composición farmacéutica |
| PE20191043A1 (es) | 2016-09-19 | 2019-08-06 | Mexichem Fluor Sa De Cv | Composicion farmaceutica |
| CN109715160A (zh) * | 2016-09-19 | 2019-05-03 | 墨西哥氟石股份公司 | 药物组合物 |
| ES2877575T3 (es) | 2016-09-19 | 2021-11-17 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende salmeterol |
| ES2956521T3 (es) * | 2016-09-19 | 2023-12-22 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende bromuro de tiotropio |
| GB2573297A (en) * | 2018-04-30 | 2019-11-06 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| FR3130554B1 (fr) | 2021-12-20 | 2024-10-18 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
| FR3137830A1 (fr) | 2022-07-13 | 2024-01-19 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
| US12383516B1 (en) | 2025-01-06 | 2025-08-12 | Amphastar Pharmaceuticals, Inc. | Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5439670A (en) | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| NZ246421A (en) | 1991-12-18 | 1996-05-28 | Minnesota Mining & Mfg | Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant |
| US7105152B1 (en) * | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| DE69530325T2 (de) | 1994-12-22 | 2004-02-19 | Astrazeneca Ab | Aerosol-arzneiformulierungen |
| WO1996032151A1 (en) | 1995-04-14 | 1996-10-17 | Glaxo Wellcome Inc. | Metered dose inhaler for fluticasone propionate |
| DE69814428T2 (de) * | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
| US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| EP1102579B1 (de) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| GB2392915B (en) | 1999-09-11 | 2004-04-28 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
| US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| CN1144582C (zh) | 2000-11-28 | 2004-04-07 | 中国药科大学 | 治疗呼吸系统疾病的无氟里昂药用气雾剂 |
| CN1216600C (zh) * | 2002-04-24 | 2005-08-31 | 信谊药厂 | 盐酸左旋沙丁胺醇气雾剂及制备工艺 |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0323685D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2006004646A1 (en) | 2004-06-28 | 2006-01-12 | Nektar Therapeutics | Aerosol formulation comprising nicotine salt |
| WO2007020204A2 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
| GB0915106D0 (en) | 2009-08-28 | 2009-10-07 | Glaxo Group Ltd | Process |
-
2011
- 2011-10-12 GB GB201117621A patent/GB201117621D0/en not_active Ceased
-
2012
- 2012-10-12 CA CA2851764A patent/CA2851764C/en active Active
- 2012-10-12 ES ES12787053.3T patent/ES2556585T3/es active Active
- 2012-10-12 AU AU2012322453A patent/AU2012322453B2/en active Active
- 2012-10-12 BR BR112014008609-5A patent/BR112014008609B1/pt active IP Right Grant
- 2012-10-12 US US14/351,001 patent/US9114164B2/en active Active
- 2012-10-12 EP EP12787053.3A patent/EP2766005B1/en active Active
- 2012-10-12 CN CN201280049813.9A patent/CN103857388B/zh active Active
- 2012-10-12 JP JP2014535166A patent/JP5818290B2/ja active Active
- 2012-10-12 MX MX2014004364A patent/MX336225B/es unknown
- 2012-10-12 WO PCT/GB2012/052542 patent/WO2013054135A1/en not_active Ceased
-
2014
- 2014-03-26 ZA ZA2014/02234A patent/ZA201402234B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2766005B1 (en) | 2015-11-25 |
| CA2851764A1 (en) | 2013-04-18 |
| US20140286877A1 (en) | 2014-09-25 |
| US9114164B2 (en) | 2015-08-25 |
| JP2014530231A (ja) | 2014-11-17 |
| CA2851764C (en) | 2017-02-14 |
| EP2766005A1 (en) | 2014-08-20 |
| MX336225B (es) | 2016-01-12 |
| AU2012322453B2 (en) | 2015-06-18 |
| BR112014008609B1 (pt) | 2022-04-12 |
| ZA201402234B (en) | 2015-03-25 |
| CN103857388A (zh) | 2014-06-11 |
| JP5818290B2 (ja) | 2015-11-18 |
| CN103857388B (zh) | 2016-09-28 |
| AU2012322453A1 (en) | 2014-04-17 |
| WO2013054135A1 (en) | 2013-04-18 |
| MX2014004364A (es) | 2014-05-27 |
| BR112014008609A2 (pt) | 2017-04-18 |
| GB201117621D0 (en) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2556585T3 (es) | Composiciones que comprenden sulfato de salbutamol | |
| ES2502472T3 (es) | Composición adhesiva para su uso en un inmunosensor | |
| AR088382A1 (es) | Formulaciones de etanercept estabilizadas con xilitol | |
| EA201290982A1 (ru) | Фармацевтические композиции, препятствующие злоупотреблению | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CL2008000022A1 (es) | Compuestos derivados de fenil-(4-fenil pirimidin-2-il)-aminas; composicion farmaceutica que comprende a dichos compuestos ; procedimiento de preparacion de dichos compuestos; y su uso en enfermedades inflamatorias, diabetes y cancer. | |
| ES2527242T3 (es) | Composiciones que comprenden un germinante y un agente antimicrobiano | |
| CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
| CR20130556A (es) | FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7 | |
| BR112014012524A2 (pt) | composições compreendendo um componente de estabilidade do prazo de validade | |
| MX2015000813A (es) | Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona. | |
| CL2008003284A1 (es) | Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras. | |
| CR20110110A (es) | Composicion farmaceutica | |
| PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
| MX2012008717A (es) | Composiciones para el cuidado oral. | |
| HK1200105A1 (zh) | 牙齒膜製劑 | |
| UY31788A (es) | Formulación farmacéutica sólida con liberación retardada | |
| GT200800107A (es) | Formulaciones orales que comprenden tigeciclina | |
| CL2007001838A1 (es) | Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih. | |
| EA201170512A1 (ru) | Композиция для перорального введения | |
| CL2013002905A1 (es) | Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares. | |
| ES2508165T3 (es) | Lactoferrina y sustancia blanca | |
| BR122020011180B8 (pt) | formulações injetáveis de compostos de tetraciclina | |
| CL2012003265A1 (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo. | |
| BR112015011515A2 (pt) | Composições farmacêuticas de inibidores de cetp |